Pediatric Cardiology

, Volume 30, Issue 3, pp 331–335 | Cite as

Promoter Polymorphism (rs3755724, -55C/T) of Tissue Inhibitor of Metalloproteinase 4 (TIMP4) as a Risk Factor for Kawasaki Disease with Coronary Artery Lesions in a Korean Population

  • Ju Yeon Ban
  • Kyung Leem Yoon
  • Su Kang Kim
  • Sungwook Kang
  • Joo-Ho Chung
Original Article

Abstract

Kawasaki disease (KD) is an acute febrile vasculitis that predominantly affects infants and young children. Tissue inhibitors of matrix metalloproteinases (TIMPs) comprise a family of four members, of which TIMP4 is characterized by its restriction to cardiovascular structures. In KD pathophysiology, TIMP4 is considered to be involved in the development of coronary artery lesions (CALs). Therefore, this study investigated single-nucleotide polymorphisms (SNPs) of the TIMP4 gene as risk factors for KD with CALs in Korean children. To observe this association, two SNPs (rs3755724, -55C/T, promoter; rs17035945, 3′-untranslated region) were genotyped in TIMP4 using direct sequencing. There were no SNPs in the coding region of TIMP4, and two SNPs were selected in the exon and promoter regions. This study recruited 250 control and 101 KD subjects. For data analysis, SNPStats, SNPAnalyzer, and Helixtree programs were used. These SNPs were not associated with KD. However, in the recessive model, a significant association was found between rs3755724 and the development of CALs in KD (P = 0.02; odds ratio, 0.31; 95% confidence interval, 0.11–0.85). The minor allele (C) of rs3755724 showed the susceptibility of CALs to risk in KD patients. These results suggest that TIMP4 is related to the development of KD with CALs in Korean children.

Keywords

Coronary artery lesion Kawasaki disease Single nucleotide polymorphism Tissue inhibitor of metalloproteinase 4 

References

  1. 1.
    Abe J (2008) Immunological aspects of Kawasaki disease. Nippon Rinsho 66:267–271PubMedGoogle Scholar
  2. 2.
    Baer AZ, Rubin LG, Shapiro CA et al (2006) Prevalence of coronary artery lesions on the initial echocardiogram in Kawasaki syndrome. Arch Pediatr Adolesc Med 160:686–690PubMedCrossRefGoogle Scholar
  3. 3.
    Baker AH, Edwards DR, Murphy G (2002) Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J Cell Sci 115:3719–3727PubMedCrossRefGoogle Scholar
  4. 4.
    Barrett JC, Fry B, Maller J, Daly MJ (2005) Haploview: analysis and visualization of linkage disequilibrium and haplotype maps. Bioinformatics 21:263–265PubMedCrossRefGoogle Scholar
  5. 5.
    Chua PK, Melish ME, Yu Q et al (2003) Elevated levels of matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 during the acute phase of Kawasaki disease. Clin Diagn Lab Immunol 10:308–314PubMedCrossRefGoogle Scholar
  6. 6.
    Egeblad M, Werb Z (2002) New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2:161–174PubMedCrossRefGoogle Scholar
  7. 7.
    Gavin PJ, Crawford SE, Shulman ST et al (2003) Systemic arterial expression of matrix metalloproteinases 2 and 9 in acute Kawasaki disease. Arterioscler Thromb Vasc Biol 23:576–581PubMedCrossRefGoogle Scholar
  8. 8.
    Ikeda K, Ihara K, Yamaguchi K et al (2008) Genetic analysis of MMP gene polymorphisms in patients with Kawasaki disease. Pediatr Res 63:182–185PubMedCrossRefGoogle Scholar
  9. 9.
    Jung MY, Kim BS, Kim YJ et al (2008) Assessment of relationship between Fyn-related kinase gene polymorphisms and overweight/obesity in Korean population. Korean J Physiol Pharmacol 12:83–87Google Scholar
  10. 10.
    Koskivirta I, Rahkonen O, Mayranpaa M et al (2006) Tissue inhibitor of metalloproteinases 4 (TIMP4) is involved in inflammatory processes of human cardiovascular pathology. Histochem Cell Biol 126:335–342PubMedCrossRefGoogle Scholar
  11. 11.
    Lee HJ, Lee GH, Nah S et al (2008) Association of TIMP-4 gene polymorphism with the risk of osteoarthritis in the Korean population. Rheumatol Int 28:845–850PubMedCrossRefGoogle Scholar
  12. 12.
    Matsubara T, Furukawa S, Yabuta K (1990) Serum levels of tumor necrosis factor, interleukin 2 receptor, and interferon-gamma in Kawasaki disease involved coronary-artery lesions. Clin Immunol Immunopathol 56:29–36PubMedCrossRefGoogle Scholar
  13. 13.
    Matsuyama T (1999) Tissue inhibitor of metalloproteinases-1 and matrix metalloproteinase-3 in Japanese healthy children and in Kawasaki disease and their clinical usefulness in juvenile rheumatoid arthritis. Pediatr Int 41:239–245PubMedCrossRefGoogle Scholar
  14. 14.
    Moreno N, Mendez-Echevarria A, de Inocencio J et al (2008) Coronary involvement in infants with Kawasaki disease treated with intravenous gamma-globulin. Pediatr Cardiol 29:31–35PubMedCrossRefGoogle Scholar
  15. 15.
    Nagase H, Woessner JF Jr (1999) Matrix metalloproteinases. J Biol Chem 274:21491–21494PubMedCrossRefGoogle Scholar
  16. 16.
    Newburger JW, Takahashi M, Gerber MA et al (2004) Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic fever, Endocarditis, and Kawasaki disease, Council on Cardiovascular disease in the Young, American Heart Association. Circulation 110:2747–2771PubMedCrossRefGoogle Scholar
  17. 17.
    Ogawa S (2008) Biochemical and immunological laboratory findings in Kawasaki disease. Nippon Rinsho 66:315–320PubMedGoogle Scholar
  18. 18.
    Park JA, Shin KS, Kim YW (2005) Polymorphism of matrix metalloproteinase-3 promoter gene as a risk factor for coronary artery lesions in Kawasaki disease. J Korean Med Sci 20:607–611PubMedCrossRefGoogle Scholar
  19. 19.
    Peng Q, Zhou TF, Chen CH et al (2005) Clinical value of serum matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 for the prediction and early diagnosis of coronary artery lesion in patients with Kawasaki disease. Zhonghua Er Ke Za Zhi 43:676–680PubMedGoogle Scholar
  20. 20.
    Rahkonen OP, Koskivirta IM, Oksjoki SM et al (2002) Characterization of the murine Timp4 gene, localization within intron 5 of the synapsin 2 gene, and tissue distribution of the mRNA. Biochim Biophys Acta 1577:45–52PubMedGoogle Scholar
  21. 21.
    Research Committee on Kawasaki Disease (1984) Report of Subcommittee on Standardization of Diagnostic Criteria and Reporting of Coronary Artery Lesions in Kawasaki Disease. Ministry of Health and Welfare, Tokyo, JapanGoogle Scholar
  22. 22.
    Senzaki H, Masutani S, Kobayashi J et al (2001) Circulating matrix metalloproteinases and their inhibitors in patients with Kawasaki disease. Circulation 104:860–863PubMedCrossRefGoogle Scholar
  23. 23.
    Sole X, Guino E, Valls J et al (2006) SNPStats: a Web tool for the analysis of association studies. Bioinformatics 22:1928–1929PubMedCrossRefGoogle Scholar
  24. 24.
    Takeshita S, Tokutomi T, Kawase H et al (2001) Elevated serum levels of matrix metalloproteinase-9 (MMP-9) in Kawasaki disease. Clin Exp Immunol 125:340–344PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Ju Yeon Ban
    • 1
  • Kyung Leem Yoon
    • 2
  • Su Kang Kim
    • 1
  • Sungwook Kang
    • 1
  • Joo-Ho Chung
    • 1
  1. 1.Kohwang Medical Research Institute, School of MedicineKyung Hee UniversitySeoulRepublic of Korea
  2. 2.Department of Pediatrics, East-West Neo Medical CenterKyung Hee UniversitySeoulRepublic of Korea

Personalised recommendations